Clinical lymphoma, myeloma & leukemia · 2025
Prognostic Utility of Quantitative PET Parameters on Baseline and Interim FDG-PET Scans in Hodgkin Lymphoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kovaleva Natalia, Wai Shin Hnin, Waters Niamh, Lee Sze-Ting, Carey Andrew, Lim Hui Z, Piercey Oliver, Scott Andrew M, Hawkes Eliza A, Chong Geoffrey
Аннотация
BACKGROUND: In classical Hodgkin lymphoma (cHL), interim positron emission tomography (iPET) using Deauville Score (DS) guides therapy. Quantitative PET parameters, including changes in maximum standard uptake value [ΔSUVmax], total metabolic tumor volume [ΔTMTV], total lesion glycolysis [ΔTLG], may enhance the predictive value of iPET.
METHODS: This retrospective study analysed 98 cHL patients from 2008 to 2022, assessing quantitative PET parameters at baseline (PET0), after 2 or 3 chemotherapy cycles (iPET), and associations with survival outcomes.
RESULTS: Advanced-stage disease was present in 45% of patients. At PET0, no parameters were significantly associated with progression-free survival (PFS). At iPET, the only quantitative parameter independently associated with inferior PFS was ΔSUVmax <72% (HR 5.1, 95% CI 1.7-15.5, P = .004). DS positivity was also independently associated with inferior PFS (HR 2.92, 95% CI 1.07-8.01, P = 037). iPET parameters of ΔTLG <99%, and ΔTMTV <99% achieved univariate but not independent statistical significance.
CONCLUSION: Larger prospective studies are needed to validate these findings and evaluate quantitative PET parameters in cHL patient risk stratification.
METHODS: This retrospective study analysed 98 cHL patients from 2008 to 2022, assessing quantitative PET parameters at baseline (PET0), after 2 or 3 chemotherapy cycles (iPET), and associations with survival outcomes.
RESULTS: Advanced-stage disease was present in 45% of patients. At PET0, no parameters were significantly associated with progression-free survival (PFS). At iPET, the only quantitative parameter independently associated with inferior PFS was ΔSUVmax <72% (HR 5.1, 95% CI 1.7-15.5, P = .004). DS positivity was also independently associated with inferior PFS (HR 2.92, 95% CI 1.07-8.01, P = 037). iPET parameters of ΔTLG <99%, and ΔTMTV <99% achieved univariate but not independent statistical significance.
CONCLUSION: Larger prospective studies are needed to validate these findings and evaluate quantitative PET parameters in cHL patient risk stratification.